Finasteride Tablet, Film Coated
Product Images NDC 50090-4697

6 FDA label images from A-s Medication Solutions · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Finasteride (NDC 50090-4697). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Finasteride Figure 1 (Finasteride Fig.1)

Finasteride Figure 1 (Finasteride Fig.1)
Line graph depicting mean change from baseline ± standard error (SE) over a period of 4 years, comparing Finasteride 5 mg tablets to placebo. The x-axis represents time points from baseline through Year 4, while the y-axis shows mean change values ranging from 0 to -6. Two lines represent Finasteride and placebo groups, with the Finasteride group showing a larger mean decrease compared to placebo throughout the study. Sample sizes for each group at each time point are indicated below the x-axis.*
FDA Label Image

Finasteride-fig.2 (Finasteride Fig.2)

Finasteride-fig.2 (Finasteride Fig.2)
A line graph comparing the cumulative percent of patients over 48 months between two groups: Finasteride and Placebo. The graph shows observation time in months on the x-axis and percent of patients on the y-axis, with Finasteride represented by a solid line and Placebo by a dashed line. Below the graph, tables provide cumulative event numbers and patients at risk per year for both groups.*
FDA Label Image

Finasteride Figure 2 (Finasteride Fig.3)

Finasteride Figure 2 (Finasteride Fig.3)
A line chart depicting mean percent change from baseline over four years for two groups: Placebo and Finasteride. The vertical axis shows mean percent change, and the horizontal axis marks Baseline to Year 4. Placebo data points increase steadily, while Finasteride data points decrease sharply and stabilize below zero. Sample sizes for each group are listed below for each time point.*
FDA Label Image

Finasteride Figure 4 (Finasteride Fig.4)

Finasteride Figure 4 (Finasteride Fig.4)
A line graph showing the percent of participants with an event over time in years from randomization up to 5.5 years. The graph compares four groups: Placebo, Finasteride, Doxazosin, and Combination, with the Placebo group having the highest event percentage and the Combination group the lowest.*
FDA Label Image

Structutre (Finasteride Structure)

Structutre (Finasteride Structure)
Chemical structure diagram of finasteride, showing its molecular framework including rings and functional groups consistent with the finasteride molecule.*
FDA Label Image

Label Image (Lbl500904697)

Label Image (Lbl500904697)
Finasteride 5 mg film-coated tablets label from A-S Medication Solutions, showing the drug name, strength, dosage form, and quantity of 90 tablets. The label includes storage instructions to keep the product at 68-77 degrees Fahrenheit and protect it from light. Other details include the NDC number 50090-4697-1 and lot number information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.